Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application.

1-37. (Canceled).

38. (Currently Amended) A method of generating a T-lymphocyte cell-mediated protective immune response against a herpes virus infection, in a mammal in need thereof, comprising co-administering to the mammal a therapeutically effective amount of Escherichia coli heat labile enterotoxin B subunit (EtxB), and an antigen, wherein the EtxB is free from whole toxin and is not linked to the antigen, wherein the antigen is a virus antigen from the herpes virus family, thereby ~~enhancing~~ generating the T-lymphocyte cell-mediated protective immune response against a herpes virus infection.

39-40. (Canceled).

41. (Previously Presented) The method according to claim 38, wherein the virus antigen is an antigen of a virus selected from the group consisting of Herpes Simplex Virus-1 (HSV-1), Herpes Simplex Virus-2 (HSV-2), Epstein-Barr Virus (EBV), Varicella-zoster Virus (VZV), Cytomegalovirus (CMV), Human Herpes Virus-6 (HHV-6), Human Herpes Virus-7 (HHV-7) and Human Herpes Virus-8 (HHV-8).

42. (Previously Presented) The method according to claim 41, wherein the virus antigen is an antigen of a virus selected from the group consisting of HSV-1, HSV-2, CMV or EBV.

43. (Canceled).

44. (Previously Presented) The method according to claim 38, wherein the said EtxB and antigen are administered to the said mammalian subject in an amount which is effective to increase the mammalian subject's levels of T cell lymphocyte response to the antigen.

45-53. (Canceled).

54. (Currently Amended) A method of generating a T-lymphocyte cell-mediated protective immune response against an infection, in a mammal in need thereof, comprising administering to the mammal between 50 and 100 μg of Escherichia coli heat labile enterotoxin B subunit (EtxB), wherein the EtxB is free from whole toxin, and an antigen, wherein the EtxB and antigen are not linked to form a single active agent.

55. (Previously Presented) The method of claim 54, wherein the EtxB and antigen are administered to the mammal in need thereof in multiple doses.

56-60. (Canceled).

61. (Previously Presented) The method of claim 38, wherein the EtxB and antigen are administered to the mammal in need thereof in multiple doses.

62-68. (Canceled).